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introduction: Pancreatic adenocarcinoma is an aggressive malignancy that has consis-
tently demonstrated poor outcomes despite aggressive treatments. Despite multimodal 
treatment, local disease progression and local recurrence are common. Management of 
recurrent or progressive pancreatic carcinomas proves a further challenge. In patients 
previously treated with radiation therapy, stereotactic body radiation therapy (SBRT) is 
a promising modality capable of delivering high dose to the tumor while limiting dose 
to critical structures. We aimed to determine the feasibility and tolerability of SBRT for 
recurrent or local pancreatic cancer in patients previously treated with external beam 
radiation therapy (EBRT).
Materials and methods: Patients treated with EBRT who developed recurrent or local 
pancreatic ductal adenocarcinoma treated with SBRT reirradiation at our institution, from 
2004 to 2014 were reviewed. Our primary endpoints included overall survival (OS), local 
control, regional control, and late grade 3+ radiation toxicity. Endpoints were analyzed 
with the Kaplan–Meier method. The association of these survival endpoints with risk 
factors was studied with univariate Cox proportional hazards models.
results: We identified 38 patients with recurrent/progressive pancreatic cancer treated 
with SBRT following prior radiation therapy. Prior radiation was delivered to a median dose 
of 50.4 Gy in 28 fractions. SBRT was delivered to a median dose of 24.5 Gy in 1–3 fractions. 
Surgical resection was performed on 55.3% of all patients. Within a median follow-up of 
24.4 months (inter-quartile range, 14.9–32.7 months), the median OS from diagnosis for 
the entire cohort was 26.6 months (95% CI: 20.3–29.8) with 2-year OS of 53.0%. Median 
survival from SBRT was 9.7 months (95% CI, 5.5–13.8). The 2-year freedom from local 
progression and regional progression was 58 and 82%, respectively. For the entire cohort, 
18.4 and 10.5% experienced late grade 2+ and grade 3+ toxicity, respectively.
conclusion: This single institution retrospective review identified SBRT reirradiation to 
be a feasible and tolerable treatment strategy for patients with previous locally progres-
sive or recurrent pancreatic adenocarcinoma.
Keywords: pancreatic cancer, stereotactic body radiation therapy, locally progressive, reirradiation, overall 
survival
TaBle 1 | Patient characteristics.
characteristics Value (n = 38 lesions)
Age (years, range) 42.7–84.8
gender
Female 19 (50%)
Male 19 (50%)
ca19-9 value [median value, inter-quartile range (iQr)]
At diagnosis 141.4 (90.3, 365.2)
Pre-stereotactic body radiation therapy (SBRT) 85.9 (20.7, 366.9)
Post-SBRT 89.3 (14.7, 458.6)
Change in CA19-9 2.2 (−15.0, 120.2)
location
Body 4 (11%)
Heal 20 (53%)
Tail 2 (5%)
Uncinate 4 (11%)
Neck 3 (8%)
Genu 0 (0%)
Multiple 5 (13%)
resectable status
Resectable 21 (55.3%)
Borderline resectable 3 (7.9%)
Unresectable 14 (36.8)
surgery
Yes 21 (55.3%)
No 17 (44.7%)
Previous external beam radiation  
therapy dose (median, range)
50.4 (14, 55.8)
Prior fx (median, range) 28 (8, 30)
Prior dose/fx (median, range) 1.8 (1.8, 3)
Treatment platform
Trilogy 15 (39%)
CyberKnife 16 (42%)
Truebeam 7 (18%)
chemotherapy
Gemcitibine 18 (51%)
Gemcitibine + capcitabine 5 (14%)
Gemcitibine + other 6 (17%)
FU based 5 (14%)
Other 1 (3%)
Gross tumor volume (cc) (median, IQR) 13.7 (8.8, 19)
Planning target volume (cc) (median, IQR) 14 (9.4, 19)
Fractionation
Single 18 (47%)
Multi-fraction 20 (53%)
Dose (median, IQR) 24.5 (24, 30)
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inTrODUcTiOn
Pancreatic adenocarcinoma is an aggressive malignancy that 
has consistently demonstrated poor outcomes despite advances 
in surgical techniques, systemic therapy, and radiation tech-
niques. Best outcomes are observed in those who receive surgi-
cal resection as it is the only potential for cure. Unfortunately, 
<20% of patients are deemed resectable at time of diagnosis. 
Additionally, systemic chemotherapy and radiation play an 
important role as adjuvant treatment, or definitive treatment in 
unresectable patients (1). Despite aggressive multimodal treat-
ment, local disease progression and recurrence are common 
(2–4). Management of locally recurrent or progressive pancre-
atic cancer has proven to be further challenge as conventional 
radiation techniques are unable to give further curative doses, 
surgery is often not an option, and systemic therapy may have 
been exhausted.
Following recurrence or disease progression, treatment options 
for local disease control remain limited. Reresection has been 
demonstrated to be safe and feasible, however, only a small pro-
portion of patients are deemed to be candidates (3, 5). Additional 
radiation therapy is also limited due to the presence of critical 
normal structures. These include small bowel, kidneys, and spinal 
cord and further radiation would cause unacceptable toxicity.
Recently, there has been interest in stereotactic body radia-
tion therapy (SBRT). SBRT is a highly precise modality that 
is capable of delivering a high biological effective dose while 
minimizing dose to surrounding tissue (6). The precision 
afforded by SBRT thereby minimizing dose to critical structures 
is promising for reirradiation. Prior retrospective reports have 
identified reirradiation as a potential treatment option (7, 8). 
Herein, we report the use of SBRT for recurrent and locally 
progressive pancreatic adenocarcinoma treated in patients with 
prior radiation therapy.
MaTerials anD MeThODs
Patient Population
Following approval of our institution review board protocol, 
patients with histologically proven pancreatic adenocarcinoma 
between 2004 and 2014, who were treated with external beam 
radiation followed by SBRT, were reviewed. Patients with resect-
able, borderline resectable, unresectable, medically inoperable, 
and recurrent tumors were included in this study. Patients were 
excluded if they had distant metastasis. SBRT was performed 
on either a CyberKnife Robotic Radiosurgery (Accuray Inc., 
Sunnyvale, CA, USA) or other linear accelerator-based platforms 
(Trilogy, TrueBeam) (Varian Medical Systems, Palo Alto, CA, 
USA). Patient variables including age, race, gender, SMAD4 
mutation, surgical status, chemotherapy treatment, prior external 
beam radiation therapy (EBRT) and SBRT dose, dosimetry, and 
late toxicity were collected.
Definition of Parameters
Local, regional, and distant progressions were determined based 
on radiographic findings on follow-up and/or confirmatory 
biopsy if done. Local progression was identified as progressive 
disease (PD) using RECIST 1.1 criteria which is characterized by 
at least a 20% increase in the sum of diameters of the tumor and a 
minimum of a 5 mm increase (9). Regional failure was defined as 
disease progression to the regional nodes defined as n1, n2, or n3 
by the JPS classification (10, 11) (or new tumor growth within the 
pancreas outside of the radiation field). Late toxicity (>3 months 
post-SBRT) was retrospectively graded with the Common 
Terminology Criteria for Adverse Events Version 4.0. Patients 
included in the study had fiducials placed before CT-simulation 
to assist with target delineation during treatment. Matching 
was done to both fiducials and soft tissue anatomy depending 
on the extent of fiducial migration, if any occurred. Patients 
were simulated in the supine position using four-dimensional 
CT-scan with IV contrast in a vacuum lock bag and wingboard. 
FigUre 1 | Treatment scheme.
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The 4D-CT scan was obtained utilizing 1.25 mm slices simulated 
in a vacuum lock bag. During the time of simulation, a motion 
study was performed during which we obtained multiple images 
during the respiratory cycle using the abdominal marker as a 
surrogate for the respiratory cycle. The signal detected from the 
abdominal surrogate was used to bin the CT images, creating a 
series of separate CT scans for each phase in the breathing cycle. 
We then contoured the gross tumor volume (GTV) to see if any 
motion was detected during the breathing cycles. If the motion 
was found to be more than 5 mm, respiratory gating was used. 
In this technique, we determined which phases of the breathing 
cycle limit the tumor motion to 5  mm and treat during those 
specific phases (12). During the patient’s treatment, an equivalent 
abdominal surrogate signal is used to control the beam on time 
of the linear accelerator. The GTV was determined based on the 
simulation CT scan and diagnostic CT scan. For patients treated 
on a linac, the planning target volume (PTV) margin was added to 
be approximately 3 mm from GTV with editing off of the bowel. 
No PTV margin was used for patients treated on CyberKnife. 
The max dose to the small bowel was limited to 25 Gy for SBRT. 
The max dose for the kidneys, liver, and cord were limited to 15, 
50, and 15, respectively. Multi-fraction SBRT was delivered every 
other day.
endpoints
Our primary endpoints included overall survival (OS), time to 
local failure, time to regional failure, and late grade 3 or greater 
radiation toxicity.
statistical analysis
Continuous variables were summarized with median and inter-
quartile range (IQR). Categorical variables were summarized 
with frequency and percentage. The survival endpoints (OS, 
time to local progression, time to regional progression, and time 
to distant progression) were analyzed with the Kaplan–Meier 
method. The association of these survival endpoints with risk 
factors was studied with univariate Cox proportional hazards 
models. To build multivariable Cox models for the survival 
endpoints, the stepwise variable selection was performed. All 
the variables from univariate models that had a p-value of <0.1 
were included as potential predictors. Variables were removed 
from the multivariable model if the p-value >0.05. All p-values 
reported are two-sided. The effect of factors on grade 2+ and 
grand 3+ toxicities was analyzed with logistic regression models.
resUlTs
Patient characteristics
A detailed list of patient characteristics can be found in Table 1. 
We identified 38 patients with pancreatic adenocarcinoma with 
prior radiation therapy treated with SBRT for recurrent (42.1%) 
or locally PD (57.9%). Median age at diagnosis was 69.0 (range 
42.7–84.8) with 50% female and 50% male. Location of the 
tumor within the pancreas included the head (53%), body (11%), 
uncinate process (11%), neck (8%), and tail (5%). Multifocal dis-
ease within the pancreas was seen in 13%. All patients received 
EBRT with a median dose of 50.4 Gy (IQR, 30–50.4). Surgical 
status at diagnosis included resectable (55.3%), borderline 
resectable (7.9%), and unresectable (36.8%). Surgical resection 
was performed on 52.6% of patients prior to SBRT and 2.6% 
of patients following SBRT. All patients who received resec-
tion underwent a Whipple procedure. Chemotherapy regimens 
inclu ded gemcitabine alone (51%), gemcitabine + capecitabine 
(14%), gemcitabine  +  other additional chemotherapy (17%), 
and 5Fu-based chemotherapy regimens (14%). A treatment 
scheme can be seen in Figure 1.
TaBle 2 | Kaplan–Meier estimates.
Kaplan–Meier estimates all cohort
Median follow-up
From diagnosis—months (inter-quartile range) 24.4 (14.9–32.7)
Median survival from diagnosis
Median survival—months (95% CI) 26.6 (20.3–29.8)
12-months 87%
24-months 53%
Median survival from stereotactic body radiation 
therapy (sBrT)
Median survival—months (95% CI) 9.7 (5.5–13.8)
12-months 44%
24-months 20%
local control from sBrT
Median time to LF (95% CI) Median not reached 
(15.4-infinity)
12-months 71%
24-months 58%
regional control from sBrT
Median time to RF (95% CI) Median not reached 
(N/A)
12-months (95% CI) 82%
24-months (95% CI) 82%
Distant metastases from sBrT
Median time to DM (95% CI) 20.2 (9.7-infinity)
12-months (95% CI) 67%
24-months (95% CI) 49%
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sBrT Treatment characteristics
In a median of 5.8  months (IQR, 4.1–12.4) after EBRT, SBRT 
was delivered by Trilogy (39%, n = 15), Truebeam (18%, n = 7), 
or CyberKnife (42%, n = 16) in either 1 fraction (47%, n = 18) 
or multiple fractions (53%, n  =  20). Patients received either 
22 or 24 Gy in 1 fraction or 36, 30, or 27 Gy in 3 fractions. One 
patient received 20 Gy in 2 fractions while all others received 3 
fractions if treated in multiple fraction regimen. For the entire 
cohort median, GTV was 13.7 cm3 (IQR 8.8–19) and PTV was 
14 cm3 (IQR 9.4–19).
Overall survival
Within a median follow-up of 24.4  months (IQR, 14.9–
32.7  months), the median OS from diagnosis for the entire 
cohort was 26.6 months (95% CI: 20.3–29.8) with 1- and 2-year 
OS of 87 and 53.0%, respectively (Table 2; Figure 2). Univariate 
and multivariate analysis demonstrated superior OS signifi-
cantly associated with recurrent lesions [p = 0.0140, HR 0.00007 
(95% CI, 0–0.14)], those who received surgery [p  =  0.0053, 
HR 0.00007 (95% CI, 0–0.58)], and GTV volume [p = 0.0288, 
HR 0.87 (95% CI, 0.77–0.99)] and inferior OS associated with 
pre-SBRT CA19-9 [p = 0.0102, HR 1.01 (95% CI, 1.002–1.018)] 
(Table 3). Median follow-up from SBRT was 7.4 months (IQR, 
3.4–18.4) with a median survival from SBRT of 9.7 months (95% 
CI, 5.5–13.8).
local control, regional control,  
and Distant Metastases
1- and 2-year freedom from local progression is 71 and 58%, 
respectively for the entire cohort. Univariate analysis demon-
strated inferior 2-year local control significantly associated 
with post-SBRT CA19-9 (p  =  0.0243) and recurrent lesions 
(p <  0.0367) (Table  4). No multivariable model was found for 
local control with the stepwise variable selection method. 1- and 
2-year freedom from regional control rates were both 82%. None 
of the variables analyzed were found to be significantly associated 
with inferior regional control on univariate or multivariate analy-
sis (Table S1 in Supplementary Material). At 1 and 2 years, the 
Kaplan–Meier estimated rate of freedom from distant metastasis 
was 67 and 49%, respectively. Univariate analysis identified pre- 
SBRT CA19-9 (p = 0.0219) and GTV volume (p = 0.0137) asso-
ciated with increased distant metastases and prior EBRT dose 
(p = 0.0314) associated with decreased distant metastases (Table 
S2 in Supplementary Material). No multivariable model was 
found for distant metastasis with the stepwise variable selection 
method.
late radiation Toxicity
For the entire cohort, 18.4 and 10.5% experienced late grade 2+ 
and grade 3+ toxicity, respectively. None of the variables analyzed 
were found to be associated with grade 2+ or grade 3+ toxicity 
on multivariate or univariate analysis (Table S3 in Supplementary 
Material). One patient experienced grade 4 toxicity which was 
duodenal stenosis requiring urgent operative intervention. Three 
patients experienced grade 3 toxicity which included nausea 
(n = 2) and enteritis (n = 1).
DiscUssiOn
This retrospective review aimed to determine the role of SBRT 
for recurrent or locally progressive pancreatic adenocarcinoma 
in patients with prior radiation therapy. As previously noted, 
despite multi-modality treatment, local control remains poor 
(13–16). Following recurrence or local progression, manage-
ment of pancreatic adenocarcinoma becomes considerably 
more challenging. Following initial resection (if the tumor 
is resectable) and chemoradiation, very few options remain 
to provide further local control after disease progression. 
Systemic chemotherapy remains critically important, as distant 
metastasis is a major cause of mortality. However, local control 
is necessary to minimize risk for distant failure (17–20). Local 
progression can have a significant effect on quality of life caus-
ing significant pain and obstruction. Additionally, up to 30% 
of patients with pancreatic cancer die with locally destructive 
pancreatic cancer (21). We now show that reirradiation with 
SBRT in 1–3 fractions with 24–36  Gy is a feasible treatment 
strategy with acceptable rates of toxicity for recurrent/progres-
sive pancreatic cancer.
As expected, our results identified surgery associated with 
improved OS on multivariate analysis. As demonstrated in 
numerous other reports, surgery continues to be essential for 
prolonged survival (11, 22, 23). Strangely, we also identified 
recurrent lesions to be significantly associated with improved 
OS. This, however, is likely a result of patients who develop 
recurrent disease previously had responsive or stable disease for 
an extended period prior to recurrence suggesting a favorable 
TaBle 3 | Univariate and multivariate analysis of overall survival from diagnosis.
Factor hazard ratio  
(95% confidence interval)
p-Value
Univariate analysis
Age 0.97 (0.94, 1.00) 0.0639
CA19-9 at diagnosis 0.9999 (0.9995, 1.0003) 0.5764
Pre-stereotactic body radiation 
therapy (SBRT) CA19-9
1.001 (1.000, 1.002) 0.0499
Post-SBRT CA19-9 1.0002 (0.9998, 1.0006) 0.3775
Change in CA19-9 1.00074 (0.99994, 1.00154) 0.0712
SMAD4 mutated vs not 1.51 (0.81, 2.82) 0.1944
Location: heal vs body 1.25 (0.36, 4.37) 0.7313
Location: tail vs body 1.12 (0.11, 11.37) 0.9207
Location: uncinate vs body 1.27 (0.27, 5.96) 0.7583
Location: neck vs BODY 2.44 (0.46, 12.96) 0.2956
Location: multiple vs body 1.68 (0.39, 7.29) 0.4880
Location: genu vs body No data –
Prior external beam radiation  
therapy dose
0.99 (0.95, 1.02) 0.4843
Modality: CyberKnife vs triology 1.00 (0.47, 2.13) 0.9151
Modality: truebeam vs triology 0.95 (0.34, 2.67) 0.9152
Recurrent lesion being treated 0.38 (0.18, 0.80) 0.0108
Gross tumor volume (GTV) 1.04 (1.01, 1.06) 0.0026
Planning target volume 1.02 (0.99, 1.04) 0.2131
Multiple fractions 1.12 (0.56, 2.26) 0.7430
Chemo: gemcitibine + capcitabine  
vs gemcitibine
1.02 (0.34, 3.05) 0.9773
Chemo: FU based vs gemcitibine 0.93 (0.30, 2.92) 0.9001
Surgery 0.27 (0.13, 0.57) 0.0005
Dose 0.96 (0.90, 1.03) 0.2462
Multivariate analysis
Recurrent lesion being treated 0.00007 (0, 0.14) 0.0140
GTV 0.87 (0.77, 0.99) 0.0288
Surgery 0.00007 (0, 0.058) 0.0053
Pre-SBRT CA19-9 1.010 (1.002, 1.018) 0.0102
FigUre 2 | Kaplan–Meier curves for overall survival and LC.
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histology. Patients considered to have locally PD, progressed 
soon after initial treatment indicating a more aggressive tumor 
biology. As our analysis for OS was from diagnosis, the extended 
survival seen in patients with recurrence was likely a result of 
their prolonged time from initial treatment to SBRT. We also 
show pre-SBRT CA19-9 associated with inferior survival. These 
results contrast previously reported results. Sutera et  al. and 
Herman et al. previously identified post-SBRT but not pre-SBRT 
CA19-9 associated with worse survival (12, 24). Notably, how-
ever, neither of these studies analyzed SBRT for recurrent/locally 
PD with prior radiation. It is possible CA19-9 values after initial 
treatment are most prognostic as an indicator of tumor response. 
In our results, CA19-9 values after initial treatment were pre-
SBRT. In the other studies, post-SBRT CA19-9 represented 
CA19-9 values following initial treatment. Notably, our results 
did not identify improved outcomes with multi-fractionation as 
has been previously identified (12, 25). This was likely due to our 
smaller sample size unable to detect this difference.
Koong et  al. previously reported on 23 patients (52.2% 
received resection) with locally recurrent pancreatic adenocar-
cinoma after prior EBRT treated with SBRT in 1 or 5 fractions. 
Median OS from diagnosis was 27.5 and 8.5 months from SBRT. 
Cumulative local, regional, and distant failure at last follow-up was 
19, 14, and 64%, respectively. Following SBRT, 26.1% of patients 
developed grade 2+ and 8.7% developed grade 3+ toxicity (7). 
Dagoglu et al. reported on 30 patients (50% received resection) 
with prior EBRT or SBRT treated with reirradiation SBRT in a 
median of 25 Gy in 5 fractions for recurrent pancreatic cancer. 
Median OS from SBRT was 14 months. The 1- and 2-year local 
control were both 78%. Late grade 3+ toxicity was observed in 
7% of patients (8). Finally, Lominska et al. reported on 28 patients 
(29% received resection) with unresectable locally recurrent or 
TaBle 4 | Univariate and multivariate analysis of local control.
Factor hazard ratio  
(95% confidence interval)
p-Value
Univariate analysis
Age 0.98 (0.92, 1.04) 0.4550
CA19-9 at diagnosis 0.99996 (0.99946, 1.00046) 0.8816
Pre-stereotactic body radiation  
therapy (SBRT) CA19-9
1.00191 (0.99991, 1.00392) 0.0616
Post-SBRT CA19-9 1.0015 (1.0002, 1.0028) 0.0243
Change in CA19-9 1.004 (0.998, 1.010) 0.1798
SMAD4 mutated vs not 2.16 (0.44, 10.65) 0.3443
Location: heal vs body 0.36 (0.07, 1.92) 0.2335
Location: tail vs body 0.43 (0.04, 4.83) 0.4920
Location: uncinate vs body 0.21 (0.02, 2.40) 0.2117
Location: neck vs body 0.62 (0.05, 7.10) 0.6979
Location: multiple vs body 0.00 (0.00, infinity)a 0.9939
Location: genu vs body No data –
Prior external beam radiation  
therapy dose
0.95 (0.89, 1.01) 0.1297
Modality: CyberKnife vs triology 0.82 (0.18, 3.69) 0.8004
Modality: Truebeam vs triology 2.19 (0.47, 10.15) 0.3156
Recurrent lesion being treated 4.31 (1.09, 16.94) 0.0367
Gross tumor volume 1.03 (0.99, 1.07) 0.1405
Planning target volume 0.97 (0.88, 1.07) 0.5741
Multiple fractions 1.64 (0.45, 5.94) 0.4522
Chemo: gemcitibine + capcitabine 
vs gemcitibine
2.86 (0.48, 17.06) 0.2490
Chemo: FU based vs gemcitibine 4.02 (0.67, 24.23) 0.1289
surgery 0.97 (0.23, 4.06) 0.9648
Dose 1.00 (0.89, 1.13) 0.9684
aThe hazard ratio is 0 because the group defined by value 1 of the variable did not have 
a local progression event.
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progressive pancreatic cancer with prior EBRT treated with SBRT 
reirradiation. Patients received a median of 22.5 Gy in 3 frac-
tions as either boost (36%) or salvage (61%) treatment. Median 
OS from SBRT was 5.9 months. 1-year survival from SBRT and 
freedom from local progression was 18 and 70%, respectively 
(26). Our data demonstrate similar results with a median OS 
from diagnosis and SBRT of 26.6 and 9.7 months, respectively. 
Additionally, we have shown similar rates of local control with 
1-year local progression-free survival of 71%. Finally, like the 
above studies, we have acceptable or similar rates of late grade 
3+ toxicity of 10.5%.
As noted, surgical reresection remains the other primary 
method of local control following disease recurrence/progres-
sion. This, however, has limited utility as very few patients are 
candidates for this treatment. Miyazaki et  al. retrospectively 
reviewed 170 patients with recurrent pancreatic cancer who 
received prior resection. Among this cohort, only 11 patients 
(6.5%) received a second resection. Patients who received a 
second resection were found to have a significantly greater 
median OS from diagnosis (78.2 vs 20.3  months, p  <  0.001). 
Median survival from reresection/diagnosis of recurrence was 
also significantly greater in patients receiving a second resec-
tion (25.0 vs 9.3  months, p  <  0.01) (3). This review did not 
assess rates of surgical complications. Although these are quite 
impressive results, it is evident that surgical reresection is an 
excellent option for recurrent pancreatic cancer but only in a 
select few patients. Considering <20% of patients can undergo 
an initial resection and only 6.5% of recurrent patients who 
previously received resection received a second resection, this 
is not a treatment option for most patients. SBRT appears to 
be a significantly less selective treatment option able to provide 
local disease control to a greater proportion of patients. Notably, 
one patient in our cohort went on to receive surgical resection 
following SBRT.
The present study adds to the currently literature of mana-
gement of recurrent/locally progressive pancreatic cancer. This 
study, however, was limited by its retrospective nature. This lead to 
prior radiation treatments not being standardized. Additionally, 
our series includes patients with locally PD who were treated 
with SBRT soon after EBRT as well as recurrent patients treated 
many months to years later. This adds heterogeneity to our popu-
lation and may have an undetected effect on toxicity. Finally, our 
toxicity may be underrepresented due to possible uncaptured 
events associated with retrospective reviews.
cOnclUsiOn
Locally progressive and recurrent pancreatic cancer is a thera-
peutic challenge, especially relative to local control. SBRT reir-
radiation is a feasible and tolerable treatment strategy for these 
patients. Due to the high precision SBRT affords, dose to critical 
structures, such as the small bowel, can be limited leading to rea-
sonable levels of grade 3+ toxicity in patients with prior radiation. 
Future prospective studies should further define the role of SBRT 
in these patients.
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